دورية أكاديمية
A multi-omics study to characterize the transdifferentiation of human dermal fibroblasts to osteoblast-like cells.
| العنوان: | A multi-omics study to characterize the transdifferentiation of human dermal fibroblasts to osteoblast-like cells. |
|---|---|
| المؤلفون: | Pihlström S; Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Määttä K; Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Öhman T; Institute of Biotechnology and Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Mäkitie RE; Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Aronen M; Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland., Varjosalo M; Institute of Biotechnology and Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Mäkitie O; Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.; Department of Molecular Medicine and Surgery and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden., Pekkinen M; Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. |
| المصدر: | Frontiers in molecular biosciences [Front Mol Biosci] 2022 Nov 17; Vol. 9, pp. 1032026. Date of Electronic Publication: 2022 Nov 17 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101653173 Publication Model: eCollection Cited Medium: Print ISSN: 2296-889X (Print) Linking ISSN: 2296889X NLM ISO Abbreviation: Front Mol Biosci Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media S.A., [2014]- |
| مستخلص: | Background: Various skeletal disorders display defects in osteoblast development and function. An in vitro model can help to understand underlying disease mechanisms. Currently, access to appropriate starting material for in vitro osteoblastic studies is limited. Native osteoblasts and their progenitors, the bone marrow mesenchymal stem cells, (MSCs) are problematic to isolate from affected patients and challenging to expand in vitro . Human dermal fibroblasts in vitro are a promising substitute source of cells. Method: We developed an in vitro culturing technique to transdifferentiate fibroblasts into osteoblast-like cells. We obtained human fibroblasts from forearm skin biopsy and differentiated them into osteoblast-like cells with ß -glycerophosphate, ascorbic acid, and dexamethasone treatment. Osteoblastic phenotype was confirmed by staining for alkaline phosphatase (ALP), calcium and phosphate deposits (Alizarin Red, Von Kossa) and by a multi-omics approach (transcriptomic, proteomic, and phosphoproteomic analyses). Result: After 14 days of treatment, both fibroblasts and MSCs (reference cells) stained positive for ALP together with a significant increase in bone specific ALP ( p = 0.04 and 0.004, respectively) compared to untreated cells. At a later time point, both cell types deposited minerals, indicating mineralization. In addition, fibroblasts and MSCs showed elevated expression of several osteogenic genes (e.g. ALPL, RUNX2, BMPs and SMADs ), and decreased expression of SOX9 . Ingenuity Pathways Analysis of RNA sequencing data from fibroblasts and MSCs showed that the osteoarthritis pathway was activated in both cell types (p_adj. = 0.003 and 0.004, respectively). Discussion: These data indicate that our in vitro treatment induces osteoblast-like differentiation in fibroblasts and MSCs, producing an in vitro osteoblastic cell system. This culturing system provides an alternative tool for bone biology research and skeletal tissue engineering. Competing Interests: OM declares consultancy to Kyowa Kirin, Alexion, Merck and Sandoz. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Pihlström, Määttä, Öhman, Mäkitie, Aronen, Varjosalo, Mäkitie and Pekkinen.) |
| References: | Cell Death Differ. 2018 Feb;25(2):229-240. (PMID: 28914882) Tissue Eng Part C Methods. 2012 Sep;18(9):658-66. (PMID: 22428545) Nat Protoc. 2013 Mar;8(3):461-80. (PMID: 23391890) Int J Mol Sci. 2021 May 26;22(11):. (PMID: 34073480) Stem Cell Reports. 2018 Jan 9;10(1):180-195. (PMID: 29276151) Conf Proc IEEE Eng Med Biol Soc. 2006;2006:521-4. (PMID: 17946838) J Biomed Mater Res A. 2017 Aug;105(8):2291-2298. (PMID: 28445604) J Mol Med (Berl). 1999 Oct;77(10):699-712. (PMID: 10606205) Calcif Tissue Int. 2014 Jan;94(1):46-54. (PMID: 23657489) J Mol Endocrinol. 2000 Oct;25(2):169-93. (PMID: 11013345) Glycoconj J. 2013 Oct;30(7):677-85. (PMID: 23519914) Oncol Rep. 2013 Dec;30(6):2785-94. (PMID: 24101171) Arch Phys Med Rehabil. 1975 Jan;56(1):36-9. (PMID: 1090278) J Cell Biochem. 1991 Aug;46(4):351-65. (PMID: 1757478) Endocrinology. 1994 Jan;134(1):277-86. (PMID: 8275945) Bone. 2014 Dec;69:30-8. (PMID: 25201465) J Bone Miner Metab. 2014 May;32(3):240-51. (PMID: 23925391) Hum Mol Genet. 2015 Oct 15;24(20):5867-79. (PMID: 26220971) J Exp Med. 2005 Mar 21;201(6):961-70. (PMID: 15781586) J Biol Chem. 2008 Jun 20;283(25):17702-11. (PMID: 18430722) Proc Natl Acad Sci U S A. 2015 May 12;112(19):6152-7. (PMID: 25918395) Cell Death Dis. 2021 Feb 1;12(2):147. (PMID: 33542209) Biomaterials. 2019 Mar;196:31-45. (PMID: 29456164) Am J Med Genet A. 2019 Dec;179(12):2393-2419. (PMID: 31633310) Int J Stem Cells. 2014 Nov;7(2):118-26. (PMID: 25473449) Sci Rep. 2018 May 31;8(1):8463. (PMID: 29855543) Nat Genet. 2016 Jul;48(7):777-84. (PMID: 27213289) Stem Cells Int. 2016;2016:8035759. (PMID: 27648077) Hum Mol Genet. 2017 Oct 1;26(19):3823-3836. (PMID: 28934392) Cell Cycle. 2016;15(2):196-212. (PMID: 26825227) Hum Mol Genet. 2015 Jan 15;24(2):371-82. (PMID: 25180020) J Bone Miner Res. 2015 Feb;30(2):309-17. (PMID: 25196529) Sci Rep. 2016 Mar 02;6:22378. (PMID: 26932182) J Cell Sci. 1999 Oct;112 ( Pt 20):3519-27. (PMID: 10504300) Front Pharmacol. 2020 May 26;11:757. (PMID: 32528290) Semin Immunol. 2018 Jun;37:53-65. (PMID: 29395681) BMC Cell Biol. 2010 Jun 23;11:44. (PMID: 20573191) Mol Genet Metab. 2011 Apr;102(4):448-52. (PMID: 21316997) Int J Biol Sci. 2012;8(2):272-88. (PMID: 22298955) Beilstein J Nanotechnol. 2021 Aug 2;12:786-797. (PMID: 34395152) Cells. 2019 Apr 30;8(5):. (PMID: 31052294) Curr Mol Pharmacol. 2015;9(1):37-47. (PMID: 25986569) FASEB J. 2020 Mar;34(3):3519-3536. (PMID: 32037627) Med Sci Monit Basic Res. 2016 Sep 26;22:95-106. (PMID: 27667570) Sci Rep. 2021 Jan 19;11(1):1760. (PMID: 33469060) J Clin Pathol. 2005 Apr;58(4):406-8. (PMID: 15790706) Tissue Eng Part A. 2015 Jan;21(1-2):115-23. (PMID: 24980654) Calcif Tissue Int. 2022 May;110(5):546-561. (PMID: 34236445) Biol Chem. 2018 Oct 25;399(11):1313-1323. (PMID: 30044759) Bone Res. 2019 Jul 8;7:19. (PMID: 31646011) J Cell Biochem. 1997 Feb;64(2):295-312. (PMID: 9027589) Front Cell Dev Biol. 2018 Jun 28;6:66. (PMID: 30003082) Lancet Healthy Longev. 2021 Sep;2(9):e580-e592. (PMID: 34723233) Nature. 2010 Apr 15;464(7291):1043-7. (PMID: 20393562) Stem Cell Res. 2014 Jan;12(1):153-65. (PMID: 24239963) J Biol Chem. 2002 Feb 1;277(5):3686-97. (PMID: 11713245) Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11201-6. (PMID: 14500910) J Cell Physiol. 2017 Nov;232(11):2957-2963. (PMID: 28425564) Nat Commun. 2020 Aug 7;11(1):3953. (PMID: 32769974) Front Biosci. 2007 May 01;12:3068-92. (PMID: 17485283) J Cell Biochem. 2004 Aug 15;92(6):1180-92. (PMID: 15258901) Endocrinology. 2001 Jul;142(7):2731-3. (PMID: 11415989) Mol Reprod Dev. 1997 Jan;46(1):75-83; discussion 83-4. (PMID: 8981367) J Clin Transl Endocrinol. 2021 Jun 06;24:100256. (PMID: 34258233) Methods. 2001 Dec;25(4):402-8. (PMID: 11846609) J Cell Mol Med. 2017 Sep;21(9):2236-2244. (PMID: 28332281) Biochem Biophys Res Commun. 2010 Jun 25;397(2):187-91. (PMID: 20493170) Mech Dev. 2001 May;103(1-2):183-8. (PMID: 11335131) J Biol Chem. 2013 Jul 12;288(28):20488-98. (PMID: 23720781) Front Physiol. 2017 Nov 14;8:929. (PMID: 29184513) J Transl Med. 2018 Jul 27;16(1):212. (PMID: 30053821) Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:6461-4. (PMID: 26737772) Bone. 2011 May 1;48(5):1043-51. (PMID: 21281751) J Clin Invest. 1989 Mar;83(3):791-5. (PMID: 2921321) Stem Cells Transl Med. 2020 Mar;9(3):403-415. (PMID: 31904196) Sci Rep. 2019 Sep 24;9(1):13758. (PMID: 31551465) Nat Commun. 2018 Mar 22;9(1):1188. (PMID: 29568061) Int J Mol Med. 2015 Aug;36(2):406-14. (PMID: 26063293) J Biol Chem. 2004 Nov 5;279(45):47109-14. (PMID: 15377660) Tissue Eng. 2002 Jul;8(3):441-52. (PMID: 12167230) Nutrients. 2019 Jun 21;11(6):. (PMID: 31234305) Cell Mol Life Sci. 2015 Apr;72(7):1347-61. (PMID: 25487608) Bioinformatics. 2019 Jun 1;35(11):1978-1980. (PMID: 30376034) J Proteome Res. 2016 Apr 1;15(4):1116-25. (PMID: 26906401) |
| فهرسة مساهمة: | Keywords: fibroblasts; in vitro method; osteoblast-like cells; osteoblastic differentiation treatment; transdifferentiation |
| تواريخ الأحداث: | Date Created: 20221205 Latest Revision: 20221206 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9714459 |
| DOI: | 10.3389/fmolb.2022.1032026 |
| PMID: | 36465561 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!